In a recent article for Drug Target Review, Taconic's Dr. Paul Volden emphasizes how humanized immune system (HIS) mouse models have enabled the development of numerous immunotherapies. HIS models contain human immune cells and can offer more translatability in drug discovery and development than genetically engineered models. There are now a wide-variety of humanized mice available from animal model vendors, including the severely immunodeficient CIEA NOG mouse as well as NOG mice with additional modifications.
In 2018 there were a record 59 US Food and Drug Administration (FDA) drug approvals, 17 of which were associated with biologic license applications, establishing a new single-year high for approved biologic therapies. According to the 2019 Pharmaprojects Pharma R&D Annual Review, biologics accounted for less than 30 percent of drugs in R&D pipelines in 2015, but three years later grew to represent four out of every 10 drugs in R&D pipelines.
Read the complete article at: drugtargetreview.com
In 2018 there were a record 59 US Food and Drug Administration (FDA) drug approvals, 17 of which were associated with biologic license applications, establishing a new single-year high for approved biologic therapies. According to the 2019 Pharmaprojects Pharma R&D Annual Review, biologics accounted for less than 30 percent of drugs in R&D pipelines in 2015, but three years later grew to represent four out of every 10 drugs in R&D pipelines.